Previous 10 | Next 10 |
Halvorsen's 13F portfolio value decreased from $34.49B to $24.74B this quarter. The number of positions decreased from 107 to 56. Viking Global increased Amazon.com, Fortive, and International Flavors & Fragrances while dropping Humana, Coupa Software, and Twilio. The top thre...
Inhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting PR Newswire SAN DIEGO , May 19, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeli...
Inhibrx (NASDAQ:INBX) stock fell ~10% on May 16 despite the company noting that its recombinant human AAT-Fc fusion protein INBRX-101 to treat patients with alpha-1 antitrypsin deficiency (AATD) was safe and tolerable in a phase 1 trial, AATD is is a genetic disorder characterized b...
INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing PR Newswire Topline results from the Phase 1 study showed a favorable safet...
Inhibrx press release (NASDAQ:INBX): Q1 GAAP EPS of -$0.80 misses by $0.20. Revenue of $0.93M (+4.5% Y/Y) misses by $0.17M. For further details see: Inhibrx GAAP EPS of -$0.80 misses by $0.20, revenue of $0.93M misses by $0.17M
Inhibrx Reports First Quarter 2022 Financial Results and Recent Corporate Highlights PR Newswire SAN DIEGO , May 9, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging...
Inhibrx Announces Formation of Scientific Advisory Board for INBRX-101 PR Newswire SAN DIEGO , April 25, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, ...
Inhibrx to Present INBRX-101 Data at ATS 2022 Annual Meeting PR Newswire SAN DIEGO , April 5, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline,...
Inhibrx Announces Details of Presentations at 2022 AACR Annual Meeting PR Newswire SAN DIEGO , March 24, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pip...
Halvorsen's 13F portfolio value decreased from $36.04B to $34.49B this quarter. The number of positions increased from 96 to 107. Viking Global added Twilio, Workday, and Aon plc while dropping Fidelity National Information Services and Snowflake. The top three positions are Ginkg...
News, Short Squeeze, Breakout and More Instantly...
Inhibrx Inc. Company Name:
INBX Stock Symbol:
NASDAQ Market:
2024-07-23 06:30:08 ET JMP Securities analyst issues MARKET PERFORM recommendation for INBX on July 23, 2024 04:40AM ET. The previous analyst recommendation was Outperform. INBX was trading at $13.49 at issue of the analyst recommendation. The overall analyst consensus :...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...
Smart Share Global Limited (EM) is expected to report for Q1 2024 American Rebel Holdings Inc. (AREB) is expected to report for Q1 2024 First Republic Bank (San Francisco, California) (FRCB) is expected to report for Q1 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ...